Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)
USD 56.04
(14.37%)
USD 56.04
(14.37%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 558 Million EUR | 29.37% |
| 2022 | 437.32 Million EUR | -10.78% |
| 2021 | 490.19 Million EUR | 4.51% |
| 2020 | 469.01 Million EUR | 0.81% |
| 2019 | 465.26 Million EUR | 5.21% |
| 2018 | 442.21 Million EUR | 8.79% |
| 2017 | 406.49 Million EUR | 24.15% |
| 2016 | 327.42 Million EUR | 17.56% |
| 2015 | 278.51 Million EUR | 20.55% |
| 2014 | 231.03 Million EUR | 18.22% |
| 2013 | 195.42 Million EUR | 17.04% |
| 2012 | 166.96 Million EUR | 2.13% |
| 2011 | 163.47 Million EUR | 5.62% |
| 2010 | 154.78 Million EUR | -4.57% |
| 2009 | 162.2 Million EUR | 12.07% |
| 2008 | 144.73 Million EUR | 10.06% |
| 2007 | 131.49 Million EUR | 9.27% |
| 2006 | 120.34 Million EUR | 8.29% |
| 2005 | 111.13 Million EUR | 22.9% |
| 2004 | 90.42 Million EUR | 11.59% |
| 2003 | 81.03 Million EUR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 191.77 Million EUR | 57.89% |
| 2024 Q2 | 149.48 Million EUR | -20.93% |
| 2023 Q4 | 121.46 Million EUR | -3.07% |
| 2023 Q2 | 140.87 Million EUR | -18.36% |
| 2023 Q1 | 172.56 Million EUR | 33.6% |
| 2023 Q3 | 125.3 Million EUR | -11.05% |
| 2023 FY | 565.76 Million EUR | 29.37% |
| 2022 Q3 | 123.58 Million EUR | 22.33% |
| 2022 FY | 437.32 Million EUR | -10.78% |
| 2022 Q1 | 131.27 Million EUR | 11.95% |
| 2022 Q2 | 101.02 Million EUR | -23.04% |
| 2022 Q4 | 129.16 Million EUR | 4.52% |
| 2021 Q1 | 124.88 Million EUR | 18.96% |
| 2021 Q4 | 117.26 Million EUR | -4.32% |
| 2021 Q3 | 122.55 Million EUR | -2.33% |
| 2021 FY | 490.19 Million EUR | 4.51% |
| 2021 Q2 | 125.48 Million EUR | 0.48% |
| 2020 Q4 | 104.97 Million EUR | 2.39% |
| 2020 FY | 469.01 Million EUR | 0.81% |
| 2020 Q1 | 148.42 Million EUR | 32.8% |
| 2020 Q2 | 113.08 Million EUR | -23.81% |
| 2020 Q3 | 102.52 Million EUR | -9.34% |
| 2019 Q3 | 110.94 Million EUR | -4.81% |
| 2019 FY | 465.26 Million EUR | 5.21% |
| 2019 Q4 | 111.76 Million EUR | 0.74% |
| 2019 Q1 | 126.01 Million EUR | 19.72% |
| 2019 Q2 | 116.54 Million EUR | -7.51% |
| 2018 FY | 442.21 Million EUR | 8.79% |
| 2018 Q4 | 105.25 Million EUR | 0.2% |
| 2018 Q3 | 105.03 Million EUR | -5.71% |
| 2018 Q2 | 111.4 Million EUR | -7.58% |
| 2018 Q1 | 120.53 Million EUR | 21.76% |
| 2017 Q1 | 107.27 Million EUR | 43.0% |
| 2017 Q2 | 95.92 Million EUR | -10.58% |
| 2017 Q3 | 104.3 Million EUR | 8.73% |
| 2017 FY | 406.49 Million EUR | 24.15% |
| 2017 Q4 | 98.99 Million EUR | -5.09% |
| 2016 Q4 | 75.01 Million EUR | -8.73% |
| 2016 Q1 | 90.15 Million EUR | 37.7% |
| 2016 Q2 | 80.06 Million EUR | -11.2% |
| 2016 Q3 | 82.19 Million EUR | 2.66% |
| 2016 FY | 327.42 Million EUR | 17.56% |
| 2015 Q4 | 65.47 Million EUR | -3.47% |
| 2015 Q1 | 73.47 Million EUR | 45.03% |
| 2015 Q2 | 71.75 Million EUR | -2.34% |
| 2015 Q3 | 67.82 Million EUR | -5.48% |
| 2015 FY | 278.51 Million EUR | 20.55% |
| 2014 FY | 231.03 Million EUR | 18.22% |
| 2014 Q2 | 59.6 Million EUR | -4.15% |
| 2014 Q4 | 50.66 Million EUR | -13.51% |
| 2014 Q3 | 58.57 Million EUR | -1.74% |
| 2014 Q1 | 62.18 Million EUR | 32.03% |
| 2013 Q4 | 47.09 Million EUR | 2.91% |
| 2013 Q2 | 49.92 Million EUR | -5.16% |
| 2013 Q1 | 52.63 Million EUR | 52.27% |
| 2013 FY | 195.42 Million EUR | 17.04% |
| 2013 Q3 | 45.76 Million EUR | -8.32% |
| 2012 Q1 | 47.64 Million EUR | 37.81% |
| 2012 Q2 | 42.5 Million EUR | -10.78% |
| 2012 Q3 | 42.24 Million EUR | -0.62% |
| 2012 Q4 | 34.56 Million EUR | -18.17% |
| 2012 FY | 166.96 Million EUR | 2.13% |
| 2011 Q4 | 34.57 Million EUR | -15.14% |
| 2011 FY | 163.47 Million EUR | 5.62% |
| 2011 Q1 | 44.32 Million EUR | 43.31% |
| 2011 Q2 | 43.83 Million EUR | -1.11% |
| 2011 Q3 | 40.74 Million EUR | -7.06% |
| 2010 Q4 | 30.93 Million EUR | -22.72% |
| 2010 Q2 | 40.75 Million EUR | -5.39% |
| 2010 FY | 154.78 Million EUR | -4.57% |
| 2010 Q3 | 40.02 Million EUR | -1.79% |
| 2010 Q1 | 43.07 Million EUR | 6.73% |
| 2009 FY | 162.2 Million EUR | 12.07% |
| 2009 Q1 | 40.63 Million EUR | 0.0% |
| 2009 Q2 | 41.86 Million EUR | 3.03% |
| 2009 Q4 | 40.35 Million EUR | 2.57% |
| 2009 Q3 | 39.34 Million EUR | -6.01% |
| 2008 FY | 144.73 Million EUR | 10.06% |
| 2007 FY | 131.49 Million EUR | 9.27% |
| 2006 FY | 120.34 Million EUR | 8.29% |
| 2005 FY | 111.13 Million EUR | 22.9% |
| 2004 FY | 90.42 Million EUR | 11.59% |
| 2003 FY | 81.03 Million EUR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AstraZeneca PLC | 8.19 Billion USD | 93.189% |
| Bristol-Myers Squibb Company PFD CONV 2 | 17.24 Billion USD | 96.764% |
| CSPC Pharmaceutical Group Limited | 7.01 Billion USD | 92.047% |
| Clarus Therapeutics Holdings, Inc. | -39.73 Million USD | 1504.43% |
| Novartis AG | 9.76 Billion USD | 94.288% |
| PT Kalbe Farma Tbk. | 3625.13 Billion USD | 99.985% |